Portola Pharmaceuticals (NASDAQ:PTLA) Getting Somewhat Favorable Media Coverage, Report Finds

News stories about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7070958274566 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Portola Pharmaceuticals (PTLA) traded up $0.72 on Thursday, reaching $47.98. 251,145 shares of the company’s stock were exchanged, compared to its average volume of 891,944. The company has a market capitalization of $3,130.00, a PE ratio of -11.11 and a beta of 1.18. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 1 year low of $29.50 and a 1 year high of $67.10.

Several analysts have issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Portola Pharmaceuticals in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 target price on the stock. Oppenheimer reaffirmed a “buy” rating and issued a $80.00 price target on shares of Portola Pharmaceuticals in a research note on Tuesday, November 7th. William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research note on Monday, January 1st. Citigroup reissued a “buy” rating and set a $74.00 target price on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th. Finally, Zacks Investment Research raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $70.65.

In other news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://weekherald.com/2018/02/15/portola-pharmaceuticals-ptla-getting-somewhat-positive-news-coverage-report-finds.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply